Changes in T cell metabolism during graft-versus-host disease

移植物抗宿主病期间 T 细胞代谢的变化

基本信息

项目摘要

 DESCRIPTION (provided by applicant): Allogeneic blood and marrow transplantation is a cure for bone marrow failure syndromes, non-malignant hematologic disorders, and certain high risk malignancies. Graft-versus-host disease (GVHD) represents the major toxicity following allogeneic transplantation and is the leading cause of non-relapse mortality in allogeneic recipients. My long-term goals are to become an independent physician-scientist working at the interface of immunology and metabolism and to characterize the metabolic changes that are specific to the T cells that cause GVHD. The overall objectives of this application are to increase my expertise in cellular metabolism, metabolomic assays and autophagy, and then to apply these new skills and knowledge to define specific metabolic changes that differentiate T cells mediating GVHD from T cells involved in beneficial and physiologic immune responses. My preliminary data support the central hypothesis that the robust stimulation of T cells during GVHD induces AMP-activated protein kinase (AMPK) activity, which then drives metabolic adaptations in T cells and facilitates alternative energy use, including the oxidation of fat. Thes adaptations then allow T cells to survive the increased demands of disease-driven activation. The rationale for the proposed research is that identification of the novel metabolic pathways upregulated in pathogenic T cells will lead to innovative and unanticipated targets for the treatment of GVHD and other T cell-mediated diseases. The central hypothesis will be tested by pursuing three specific aims: 1) Elucidate AMPK's role in driving glucose and fatty acid metabolism in alloreactive T cells, 2) Determine the importance of AMPK in driving alloreactive T cell autophagy and 3) Determine the necessity of AMPK during anti-viral T cell responses. Aim 1 will use a mass spectrometry-based approach to quantitate glycolytic, pentose phosphate, and TCA-cycle metabolism in alloreactive T cells from wildtype (wt) or AMPK-/- donors. Aim 2 will use a combination of biochemical and imaging approaches to measure autophagy in wt or AMPK-/- T cells, as well as determine the GVHD potential of T cells lacking key autophagy proteins. Aim 3 will utilize a viral infection model in mice with either AMPK sufficient, or deficient, T cells to determine the necessity of AMPK during a viral response. The outcomes from these studies are expected to have a positive impact by defining specific metabolic changes in GVHD-causing T cells that will likely lead to new therapeutic targets for the treatment of GVHD and other T cell-mediated immune disorders. Thus, these studies are directly relevant to the mission of reducing disease so that people can live longer and more fulfilling lives. My overall career goal is to become an independent physician-scientist working at the interface of immunology and metabolism. By the end of my mentored training period, I will confidently execute metabolism-based experiments to uncover novel metabolic mechanisms present during immune responses in vivo. This will come about through dedicated attention to four training areas: 1) Improve my knowledge of cellular metabolism, metabolomic analysis and metabolic flux analysis, 2) Increase my expertise in autophagy and the execution of autophagy-based experiments, 3) Extend my knowledge of alloimmunity beyond GVHD, and 4) Refine my written and oral presentation skills, particularly in regards to grant writing, oral presentations, and manuscript preparation. The proposed studies will expose me to cellular metabolism and the methods involved in metabolomic profiling, including study design, metabolite extraction, and mass spectrometer utilization. Investigation of autophagy and interactions with autophagy experts at the University of Pittsburgh will increase my expertise in autophagy-based assays. The many seminars, journal clubs, and lab meetings at the Thomas E. Starzl Transplantation Institute, and within the Department of Immunology, will broaden my knowledge of alloimmunity and transplantation immunology. Presentation of my findings at local, regional, and national conferences will increase my written and oral presentation skills. Formal training activities, including workshops on isotope labeling, coursework on metabolic pathways, and seminars on grant writing and leadership development will supplement my hands-on training. Finally, the expertise of my mentor and scientific advisory committee, in combination with the outstanding core facilities and academic environment at the University of Pittsburgh, will ensure the success of my scientific and training goals and help establish my future career as an independent physician scientist.
 描述(由申请人提供):同种异体血液和骨髓移植是治疗骨髓衰竭综合征、非恶性血液病和某些高危恶性肿瘤的一种方法。移植物抗宿主病(GVHD)是异基因移植后的主要毒性反应,也是异基因受体非复发性死亡的主要原因。我的长期目标是成为一名独立的医学科学家,从事免疫学和代谢的研究,并描述导致GVHD的T细胞特有的代谢变化。本申请的总体目标是增加 我在细胞代谢,代谢组学测定和自噬方面的专业知识,然后应用这些新的技能和知识来定义特定的代谢变化,将介导GVHD的T细胞与参与有益和生理免疫应答的T细胞区分开来。我的初步数据支持核心假设,即GVHD期间T细胞的强烈刺激诱导AMP活化蛋白激酶(AMPK)活性,然后驱动T细胞的代谢适应并促进替代能源的使用,包括脂肪的氧化。然后,这些适应使T细胞能够在疾病驱动的激活的需求增加的情况下生存。这项研究的基本原理是,鉴定致病性T细胞中上调的新代谢途径将为治疗GVHD和其他T细胞介导的疾病带来创新和意想不到的靶点。将通过追求三个具体目标来测试中心假设:1)阐明AMPK在同种异体反应性T细胞中驱动葡萄糖和脂肪酸代谢的作用,2)确定AMPK在驱动同种异体反应性T细胞自噬中的重要性,以及3)确定AMPK在抗病毒T细胞应答期间的必要性。目标1将使用基于质谱的方法来定量来自野生型(wt)或AMPK-/-供体的同种异体反应性T细胞中的糖酵解、戊糖磷酸和TCA循环代谢。目标2将使用生物化学和成像方法的组合来测量wt或AMPK-/- T细胞中的自噬,以及确定缺乏关键自噬蛋白的T细胞的GVHD潜力。目的3将利用病毒感染模型,在小鼠中具有AMPK充足或缺乏的T细胞,以确定在病毒应答期间AMPK的必要性。这些研究的结果预计将产生积极的影响,通过定义引起GVHD的T细胞的特定代谢变化,这可能会导致新的治疗靶点,用于治疗GVHD和其他T细胞介导的免疫疾病。因此,这些研究直接关系到减少疾病的使命,使人们能够活得更长,更充实的生活。我的总体职业目标是成为一名独立的医生科学家, 免疫学和新陈代谢的界面。在我的指导培训期结束时,我将自信地执行基于代谢的实验,以揭示体内免疫反应期间存在的新代谢机制。这将通过专注于四个培训领域来实现:1)提高我对细胞代谢,代谢组学分析和代谢通量分析的知识,2)增加我在自噬和基于自噬的实验执行方面的专业知识,3)将我对同种异体免疫的知识扩展到GVHD之外,以及4)完善我的书面和口头陈述技能,特别是在拨款写作,口头陈述, 和手稿准备。拟议的研究将使我接触到细胞代谢和代谢组学分析所涉及的方法,包括研究设计,代谢物提取和质谱仪的利用。对自噬的研究以及与匹兹堡大学自噬专家的互动将增加我在基于自噬的检测方面的专业知识。在托马斯E. Starzl移植研究所,并在免疫学系,将扩大我的同种免疫和移植免疫学的知识。在地方、区域和国家会议上介绍我的研究结果将提高我的书面和口头陈述技能。正式的培训活动,包括同位素标记研讨会,代谢途径的课程,以及关于赠款写作和领导力发展的研讨会将补充我的实践培训。最后,我的导师和科学咨询委员会的专业知识,结合匹兹堡大学优秀的核心设施和学术环境,将确保我的科学和培训目标的成功,并帮助建立我未来的职业生涯作为一个独立的医生科学家。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Craig Alan Byersdorfer其他文献

Craig Alan Byersdorfer的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Craig Alan Byersdorfer', 18)}}的其他基金

FSTL-1 Regulated Pathways in Hematopoietic Stem Cell Homeostasis and Transplantation
FSTL-1 在造血干细胞稳态和移植中的调节途径
  • 批准号:
    10618130
  • 财政年份:
    2022
  • 资助金额:
    $ 15.61万
  • 项目类别:
FSTL-1 Regulated Pathways in Hematopoietic Stem Cell Homeostasis and Transplantation
FSTL-1 在造血干细胞稳态和移植中的调节途径
  • 批准号:
    10354774
  • 财政年份:
    2022
  • 资助金额:
    $ 15.61万
  • 项目类别:
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
  • 批准号:
    10561642
  • 财政年份:
    2019
  • 资助金额:
    $ 15.61万
  • 项目类别:
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
  • 批准号:
    10359032
  • 财政年份:
    2019
  • 资助金额:
    $ 15.61万
  • 项目类别:
Changes in T cell metabolism during graft-versus-host disease
移植物抗宿主病期间 T 细胞代谢的变化
  • 批准号:
    9032915
  • 财政年份:
    2016
  • 资助金额:
    $ 15.61万
  • 项目类别:

相似海外基金

Pharmacological targeting of AMP-activated protein kinase for immune cell regulation in Type 1 Diabetes
AMP 激活蛋白激酶对 1 型糖尿病免疫细胞调节的药理学靶向
  • 批准号:
    2867610
  • 财政年份:
    2023
  • 资助金额:
    $ 15.61万
  • 项目类别:
    Studentship
Establishing AMP-activated protein kinase as a regulator of adipose stem cell plasticity and function in health and disease
建立 AMP 激活蛋白激酶作为脂肪干细胞可塑性和健康和疾病功能的调节剂
  • 批准号:
    BB/W009633/1
  • 财政年份:
    2022
  • 资助金额:
    $ 15.61万
  • 项目类别:
    Fellowship
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
  • 批准号:
    532989-2019
  • 财政年份:
    2021
  • 资助金额:
    $ 15.61万
  • 项目类别:
    Postdoctoral Fellowships
Metabolic control of integrin membrane traffic by AMP-activated protein kinase controls cell migration.
AMP 激活的蛋白激酶对整合素膜运输的代谢控制控制着细胞迁移。
  • 批准号:
    459043
  • 财政年份:
    2021
  • 资助金额:
    $ 15.61万
  • 项目类别:
    Studentship Programs
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
  • 批准号:
    532989-2019
  • 财政年份:
    2020
  • 资助金额:
    $ 15.61万
  • 项目类别:
    Postdoctoral Fellowships
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
  • 批准号:
    10561642
  • 财政年份:
    2019
  • 资助金额:
    $ 15.61万
  • 项目类别:
Determining the role of AMP-activated protein kinase in the integration of skeletal muscle metabolism and circadian biology
确定 AMP 激活蛋白激酶在骨骼肌代谢和昼夜节律生物学整合中的作用
  • 批准号:
    532989-2019
  • 财政年份:
    2019
  • 资助金额:
    $ 15.61万
  • 项目类别:
    Postdoctoral Fellowships
Treating Diabetic Inflammation using AMP-Activated Protein Kinase Activators
使用 AMP 激活的蛋白激酶激活剂治疗糖尿病炎症
  • 批准号:
    2243045
  • 财政年份:
    2019
  • 资助金额:
    $ 15.61万
  • 项目类别:
    Studentship
The Role of AMP-activated Protein Kinase in GVHD-causing T Cells
AMP 激活的蛋白激酶在引起 GVHD 的 T 细胞中的作用
  • 批准号:
    10359032
  • 财政年份:
    2019
  • 资助金额:
    $ 15.61万
  • 项目类别:
Investigating the therapeutic potential of AMP-activated protein kinase in myotonic dystrophy type 1
研究 AMP 激活蛋白激酶在 1 型强直性肌营养不良中的治疗潜力
  • 批准号:
    428988
  • 财政年份:
    2019
  • 资助金额:
    $ 15.61万
  • 项目类别:
    Studentship Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了